What essential knowledge about cerebral venous sinus thrombosis should a medical student master?

Essential Knowledge for Medical Students: Cerebral Venous Sinus Thrombosis

Core Epidemiology and Demographics

Medical students must recognize that cerebral venous thrombosis (CVT) is an uncommon stroke subtype affecting predominantly young adults, with 78% of cases occurring in patients under 50 years of age. 1 CVT accounts for only 0.5-1% of all strokes but carries significant morbidity and mortality if missed. 1, 2 The condition disproportionately affects women of childbearing age, particularly those using oral contraceptives. 1

Critical Risk Factors to Memorize

High-Yield Prothrombotic Conditions

• Oral contraceptives: Increase CVT risk with an odds ratio of 5.59 (95% CI 3.95-7.91), and this risk dramatically escalates to OR 30.0 for factor V Leiden carriers and OR 79.3 for prothrombin mutation carriers who use oral contraceptives. 1
• Pregnancy and puerperium: Major risk factors in women of reproductive age. 1
• Inherited thrombophilias: Factor V Leiden, prothrombin gene mutation, deficiencies of antithrombin III, protein C, and protein S. 1
• Cancer: Present in 7.4% of CVT cases, particularly hematologic malignancies. 1
• Infections: Parameningeal infections (ear, sinus, mouth, face, neck) explain 8.2% of adult cases but 40% of pediatric CVT. 1

Clinical Presentation: The Diagnostic Challenge

Two Fundamental Mechanisms

CVT presents through two pathophysiologic mechanisms that students must distinguish: 1

1. Increased intracranial pressure from impaired venous drainage
2. Focal brain injury from venous ischemia/infarction or hemorrhage

Cardinal Clinical Features

Headache is the dominant symptom, occurring in nearly 90% of patients, typically diffuse and progressive over days to weeks. 1 Critically, 25% of patients present with isolated headache without focal signs or papilledema, creating a major diagnostic pitfall. 1

Seizures occur in 40% of patients—a key distinguishing feature from arterial stroke. 1 This high seizure frequency is pathognomonic and should immediately raise suspicion for CVT over arterial stroke.

Additional presentations include:

• Papilledema and sixth nerve palsy (diplopia) suggesting idiopathic intracranial hypertension. 1
• Focal deficits: Hemiparesis and aphasia most common. 1
• Bilateral involvement: Particularly with deep venous system thrombosis causing bilateral thalamic infarction and altered consciousness. 1
• Thunderclap headache: Mimicking subarachnoid hemorrhage in a minority. 1

Location-Specific Syndromes

• Superior sagittal sinus (most common): Headache, increased ICP, papilledema, motor deficits, seizures, scalp edema, dilated scalp veins. 1
• Lateral sinus: Ear/mastoid pain, signs of middle ear infection, increased ICP. 1
• Deep venous system (16% of cases): Rapid neurological deterioration, bilateral thalamic/basal ganglia infarction, altered consciousness. 1

Diagnostic Imaging Algorithm

Initial Approach

Plain CT or MRI alone is insufficient—a negative study does not exclude CVT. 1 Non-contrast CT is abnormal in only 30% of cases. 1

Gold Standard Imaging

MRI with MR venography (MRV) is the gold standard for CVT diagnosis. 2 When MRI is unavailable or contraindicated, CT venography (CTV) is the alternative. 1

Key Imaging Findings

• Hyperdense sinus sign on non-contrast CT: Hyperdensity (>70 Hounsfield units) in thrombosed sinus, present in only one-third of cases. 1, 3
• Empty delta sign on contrast-enhanced CT: Central hypointensity with surrounding enhancement in superior sagittal sinus. 1
• Absence of flow void on MRI with altered signal intensity in dural sinus. 1
• Hemorrhagic venous infarction: Crosses arterial territories, particularly suspicious when near a venous sinus. 1

Students must recognize that the hyperdense sinus sign (HDSS) on admission CT predicts worse outcomes, including lower rates of excellent functional outcome (71% vs 82%) and higher remote seizure rates (9% vs 3%). 3

Mandatory Imaging Protocol

If initial plain CT/MRI is negative but clinical suspicion remains, immediately proceed to CTV or MRV. 1 Catheter angiography is reserved for inconclusive cases with persistent high suspicion. 1

Laboratory Evaluation

Initial Workup

• Complete blood count, chemistry panel, PT/aPTT. 1
• Screen for prothrombotic conditions: oral contraceptive use, inflammatory diseases, infections. 1

D-Dimer Limitations

D-dimer testing cannot be recommended to rule out CVT and should not be routinely performed. 4 Unlike DVT/PE, D-dimer has poor specificity and variable sensitivity in CVT. 1

Thrombophilia Screening

Not routinely recommended for all CVT patients. 4 Consider only in: young patients, spontaneous CVT, recurrent thrombosis, positive family history of venous thromboembolism, or when results would change management. 4

Treatment: The Life-Saving Algorithm

Immediate Management

Initiate anticoagulation with IV unfractionated heparin or subcutaneous low-molecular-weight heparin (LMWH) immediately upon diagnosis, even in the presence of intracranial hemorrhage. 1 This is the most critical teaching point: hemorrhage from CVT is NOT a contraindication to anticoagulation. 1

LMWH is preferred over unfractionated heparin in the acute phase. 4

Duration of Anticoagulation

The duration algorithm is straightforward: 1

• Transient reversible risk factor (e.g., infection): 3-6 months of oral anticoagulation
• Low-risk thrombophilia or idiopathic: 3-12 months
• High-risk inherited thrombophilia, recurrent CVT, or additional venous thrombosis: Lifelong anticoagulation

Following the acute phase, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for 3-12 months. 4

Escalation for Deterioration

If patients deteriorate despite adequate anticoagulation: 1

1. Endovascular therapy (thrombolysis ± mechanical thrombectomy): Consider for severe symptoms or worsening despite anticoagulation. 1, 4 Recent evidence shows 79% achieve good clinical outcomes (mRS 0-2) with EVT. 5
2. Decompressive hemicraniectomy: Lifesaving procedure for severe mass effect or impending herniation. 1, 4

Prognosis and Outcomes

Temporal Patterns

Symptom onset is: 1

• Acute (<48 hours): 37%
• Subacute (48 hours to 30 days): 56%
• Chronic (>30 days): 7%

Median delay from symptom onset to diagnosis is 7 days, highlighting the diagnostic challenge. 1

Outcome Determinants

Early diagnosis and treatment dramatically improve outcomes. 2 Mortality in severe CVT remains as high as 34.2%, but overall prognosis is favorable with timely intervention. 6 Up to 15% of patients die in the acute phase. 7

Critical Pitfalls to Avoid

1. Never exclude CVT based on normal non-contrast CT or MRI alone—always obtain venography if suspicion exists. 1
2. Never withhold anticoagulation due to hemorrhagic transformation—hemorrhage from CVT is an indication, not contraindication, for anticoagulation. 1
3. Never dismiss isolated headache in young women on oral contraceptives—25% of CVT presents without focal signs. 1
4. Never assume bilateral deficits or paraparesis indicates arterial stroke—this pattern suggests sagittal sinus or deep venous thrombosis. 1
5. Never rely on D-dimer to exclude CVT—it lacks adequate sensitivity and specificity for this purpose. 4

Special Populations

Pregnancy and Postpartum

Women with previous CVT should receive LMWH prophylaxis throughout pregnancy and for at least 6 weeks postpartum. 4 Those with CVT related to combined hormonal contraceptives must permanently discontinue estrogen-progestagen combinations due to high recurrence risk. 4

Vaccine-Associated CVT

CVT occurring within weeks of SARS-CoV-2 vector vaccination may indicate vaccine-induced immune thrombotic thrombocytopenia (VITT), characterized by severe thrombocytopenia. 4 This requires specific recognition and management protocols.